COVID-19 and financial toxicity in patients with renal cell carcinoma
- PDF / 750,278 Bytes
- 7 Pages / 595.276 x 790.866 pts Page_size
- 13 Downloads / 155 Views
ORIGINAL ARTICLE
COVID‑19 and financial toxicity in patients with renal cell carcinoma Michael D. Staehler1 · Dena J. Battle2 · Cristiane D. Bergerot3 · Sumanta Kumar Pal3 · David F. Penson4 Received: 27 July 2020 / Accepted: 1 October 2020 © The Author(s) 2020
Abstract Purpose To ascertain renal cell carcinoma (RCC) financial toxicity on COVID-19 during the COVID-19 crisis as patients are struggling with therapeutic and financial implications. Methods An online survey was conducted from March 22 to March 25, 2020. It included baseline demographic, clinicopathologic, treatment-related information, anxiety levels related to COVID-19, questions related to financial concerns about COVID-19 as well as the validated 11-item COST measure. Results Five-hundred-and-thirty-nine patients (39%:58% male:female) from 14 countries responded. 23% of the patients did not feel in control of their financial situation but 8% reported being very satisfied with their finances. The median COST score was 21.5 (range 1–44). Metastatic patients who have not started systemic therapy had a COST score (19.8 range 2–41) versus patients on oral systemic therapy had a COST score (23.9 range 4–44). Patients in follow-up after surgery had a median COST score at 20.8 (range 1–40). A low COST scores correlated (p US $100,000) (93% vs 82%, p
Data Loading...
